These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11451695)

  • 1. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.
    Ackermann G; Tang YJ; Kueper R; Heisig P; Rodloff AC; Silva J; Cohen SH
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2348-53. PubMed ID: 11451695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
    J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
    Walkty A; Boyd DA; Gravel D; Hutchinson J; McGeer A; Moore D; Simor A; Suh K; Taylor G; Miller M; Mulvey MR;
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
    Carman RJ; Genheimer CW; Rafii F; Park M; Hiltonsmith MF; Lyerly DM
    Anaerobe; 2009 Dec; 15(6):244-8. PubMed ID: 19818865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.
    Bachoual R; Ouabdesselam S; Mory F; Lascols C; Soussy CJ; Tankovic J
    Microb Drug Resist; 2001; 7(3):257-61. PubMed ID: 11759087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile.
    Ackermann G; Tang-Feldman YJ; Schaumann R; Henderson JP; Rodloff AC; Silva J; Cohen SH
    Clin Microbiol Infect; 2003 Jun; 9(6):526-30. PubMed ID: 12848728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile.
    Schmidt C; Löffler B; Ackermann G
    Diagn Microbiol Infect Dis; 2007 Sep; 59(1):1-5. PubMed ID: 17509804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR.
    Spigaglia P; Carattoli A; Barbanti F; Mastrantonio P
    Mol Cell Probes; 2010 Apr; 24(2):61-7. PubMed ID: 19837154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I; Fantinato C; Cruaud P; Collignon A
    Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.
    Huang H; Wu S; Wang M; Zhang Y; Fang H; Palmgren AC; Weintraub A; Nord CE
    Int J Antimicrob Agents; 2009 Apr; 33(4):339-42. PubMed ID: 19097757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance in European Clostridium difficile clinical isolates.
    Spigaglia P; Barbanti F; Mastrantonio P;
    J Antimicrob Chemother; 2011 Oct; 66(10):2227-34. PubMed ID: 21771851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The characteristics of Clostridium difficile ST81, a new PCR ribotype of toxin A- B+ strain with high-level fluoroquinolones resistance and higher sporulation ability than ST37/PCR ribotype 017.
    Wang B; Peng W; Zhang P; Su J
    FEMS Microbiol Lett; 2018 Sep; 365(17):. PubMed ID: 30085003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C; Hogan T; White P; Tapsall J
    Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.
    Maurin M; Abergel C; Raoult D
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2098-105. PubMed ID: 11408229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
    Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
    Adams DA; Riggs MM; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.